Volver a Agenda
Session 4, Track B: Decentralized Clinical Trials – Canada’s First Case Study and Next Steps
Session Chair(s)
Stephanie Anderson, MS
Associate Director, Regulatory Affairs, Intrinsik Corp., Canada
The global COVID-19 pandemic has catalyzed substantial advancements in the establishment and execution of decentralized clinical trials (DCTs) in Canada. This session will offer a glimpse into the experiences and findings from Canada’s first fully decentralized trial. Furthermore, we will delve into a proposed framework for hybrid DCTs, sharing experiences to date, lessons learned, and a vision for the future. Keeping our commitment to patient-centricity, we will also discuss the perceived advantages and challenges of DCTs from the perspectives of patients, caregivers, and their families.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe different DCT models and understand methods to implement them
- Discuss the advantages and challenges with implementing DCTs
- Recognize the patient perspective when implementing DCTs
Speaker(s)
Aneta Woroniecka-Osio, MD
Manager, SCI, Bayer, Canada
Operational Implementation of Decentralized Clinical Trials advances participant-centric research
Roel Schlijper-Bos
Clinical Research Unit Manager , BC Cancer, Canada
Decentralized Clinical Trials – BC Cancer Perspective and Experiences
Maureen Smith, MED
Member, Clinical Trials Ontario College of Lived Experience, Canada
Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: “It’s About Time We Bring Trials to People”
Emily I McIntosh, PHD
College of Lived Experience Member, Clinical Trials Ontario, Canada
Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: “It’s About Time We Bring Trials to People”
Dawn P. Richards, PHD
Director, Patient and Public Engagement, Clinical Trials Ontario, Canada
Participant Perception of Decentralized Clinical Trials and Next Steps
¿Tiene una cuenta?